View Older Stories View More Recent Stories

Feb 28, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Interim Results from Ongoing Phase 1/2 Study of ARO-C3
Feb 28, 2023 07:30AM Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Feb 15, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Gains Full Rights to NASH Candidate ARO-PNPLA3
Feb 15, 2023 07:30AM Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
Feb 6, 2023 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Feb 2, 2023 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Jan 25, 2023 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Jan 9, 2023 07:30AM Takeda (TAK) and Arrowhead (ARWR) Report Topline Results from SEQUOIA Phase 2 Study of Fazirsiran
Jan 9, 2023 07:30AM Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dec 21, 2022 04:00PM Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 07:30AM Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Dec 20, 2022 07:30AM Arrowhead (ARWR) Receives $25M Milestone Payment from Amgen (AMGN)
Dec 20, 2022 07:30AM Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Dec 15, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 8, 2022 08:04AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) enrolls first patient in HZN-457 phase 1 trial for gout
Dec 8, 2022 08:00AM Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Dec 8, 2022 08:00AM Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Nov 28, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Nov 21, 2022 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 14, 2022 04:30PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
Nov 9, 2022 08:11AM Arrowhead Pharmaceuticals (ARWR) Sells Royalty Interest in Olpasiran to Royalty Pharma (RPRX) for $250 Million and Future Milestones
Nov 9, 2022 08:10AM Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Nov 7, 2022 04:09PM Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data
Nov 7, 2022 04:08PM Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Oct 13, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 11, 2022 07:30AM Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Sep 1, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Aug 17, 2022 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 17, 2022 07:30AM Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 4, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Jul 20, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
Jul 8, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 5, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
Jun 27, 2022 06:02AM Takeda Pharmaceutical (TAK) and Arrowhead (ARWR) Announce Publication of Results from Phase 2 Study of Fazirsiran
Jun 27, 2022 06:00AM Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Jun 7, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
May 26, 2022 07:30AM Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 10, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 9, 2022 10:30AM Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 2, 2022 07:33AM Arrowhead Pharmaceuticals (ARWR) Appoints Victoria Vakiener to its Board
May 2, 2022 07:31AM Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 2, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
Apr 27, 2022 07:30AM Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
Apr 26, 2022 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Commences Phase 2 GATEWAY Study of Investigational ARO-ANG3
Apr 26, 2022 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Apr 25, 2022 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Apr 25, 2022 07:30AM Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Apr 20, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
Apr 6, 2022 07:30AM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Apr 1, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
View More Recent Stories View Older Stories